Current Report Filing (8-k)
February 15 2022 - 8:06AM
Edgar (US Regulatory)
0001581280
false
0001581280
2022-02-10
2022-02-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 10, 2022
Twist Bioscience Corporation
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-38720
|
|
46-2058888
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I. R. S. Employer
Identification No.)
|
681 Gateway Boulevard
South San Francisco, CA 94080
(Address of principal executive offices, including
ZIP code)
(800) 719-0671
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
TWST
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On February 10, 2022, Twist Bioscience Corporation (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs &
Co. LLC, and Cowen and Company LLC, as the representatives of the several underwriters named therein (collectively, the “Underwriters”),
pursuant to which the Company agreed to issue and sell an aggregate of 5,227,272 shares of its common stock, including 681,818 shares
pursuant to an option granted to the Underwriters to purchase such additional shares that was exercised in full (collectively, the “Shares”),
to the Underwriters (the “Offering”). The Shares will be sold to the Underwriters at a public offering price of $55.00 per
share, less the underwriting discount and commissions. The Underwriting Agreement contains customary representations and warranties, conditions
to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under the Securities
Act of 1933, as amended.
The Offering is being made pursuant to the Company’s
registration statement on Form S-3 (Registration No. 333-238906), which was filed with the Securities and Exchange Commission
(the “SEC”) on June 3, 2020, and the prospectus supplement dated February 10, 2022 filed by the Company with the
SEC. The Offering is scheduled to close on or about February 15, 2022, subject to customary closing conditions.
The foregoing description of the Underwriting Agreement does not
purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the
Underwriting Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference.
A copy of the opinion and consent of Orrick, Herrington &
Sutcliffe LLP relating to the validity of the Shares issued in connection with the Offering is filed herewith as Exhibit 5.1 and Exhibit
23.1, respectively.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 15, 2022
|
Twist Bioscience Corporation
|
|
|
|
/s/ William E. Solis
|
|
William E. Solis
Associate General Counsel, Corporate
and Assistant Secretary
|
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024